Psoriasis: A Complete Guide to Understanding and Managing Psoriasis

If you or someone you know has psoriasis, you have probably heard it described as “just a skin condition.” But if you live with it, you know it is far more than that. Those thick, silvery-white patches that crack, bleed, and itch are the visible part of a disease that often affects joints, cardiovascular health, and emotional well-being.

The encouraging news is that psoriasis treatment has advanced dramatically in the past two decades. We now have therapies that can clear the skin almost entirely for many patients. This guide covers what psoriasis actually is, why it happens, the full range of treatment options, and the integrative strategies that can support your overall health alongside conventional care.

What Is Psoriasis?

Psoriasis is a chronic autoimmune disease in which the immune system sends faulty signals that speed up the growth cycle of skin cells. Normally, new skin cells form deep in the skin and slowly rise to the surface over about a month, then quietly shed. In psoriasis, this process is compressed to just three or four days. The result is a pileup of cells on the skin surface that forms the characteristic raised, red (or dark) patches covered with silvery scales.^[1]

Unlike eczema, which is driven primarily by the Th2 arm of the immune system, psoriasis involves the Th17 and Th1 pathways. Key inflammatory molecules include tumor necrosis factor alpha (TNF-alpha), interleukin-17 (IL-17), and interleukin-23 (IL-23). Understanding these pathways has been the basis for a revolution in treatment.^[2]

Psoriasis is not contagious. You cannot get it from touching someone who has it. And while it can start at any age, it most commonly appears for the first time between the ages of 15 and 35, with a second peak around ages 50 to 60.^[3]

Types of Psoriasis

Psoriasis takes several forms, and it is possible to have more than one type at the same time or to transition from one type to another.

Plaque Psoriasis

By far the most common type, accounting for about 80-90% of cases. It presents as well-defined, raised patches (plaques) of red or darkened skin topped with silvery-white scales. Common locations include the elbows, knees, lower back, and scalp. Plaques can range from small spots to areas covering large portions of the body.^[1]

Guttate Psoriasis

Characterized by small, drop-shaped spots, guttate psoriasis often appears suddenly, typically in children or young adults. It is frequently triggered by a streptococcal throat infection. In many cases it resolves on its own within weeks to months, though some people go on to develop chronic plaque psoriasis.^[4]

Inverse Psoriasis

This type shows up in skin folds: the armpits, groin, under the breasts, and between the buttocks. Instead of thick scales, inverse psoriasis produces smooth, shiny, red patches that can be confused with fungal infections. Friction and sweating make this type particularly uncomfortable.

Pustular Psoriasis

Marked by white, pus-filled bumps (pustules) surrounded by red skin. The pus is not infected; it consists of white blood cells. Pustular psoriasis can be localized (often on the palms and soles) or generalized across the body, which is a medical emergency requiring immediate care.^[5]

Erythrodermic Psoriasis

The rarest and most severe form, erythrodermic psoriasis causes widespread redness and shedding of skin over large areas of the body. It can disrupt the body’s ability to regulate temperature and fluid balance and requires urgent medical attention. It can be triggered by severe sunburn, abrupt withdrawal of systemic steroids, or poorly controlled psoriasis.^[5]

Nail Psoriasis

Up to 50% of people with plaque psoriasis and about 80% of those with psoriatic arthritis develop nail changes. These can include pitting (tiny dents), discoloration (yellow-brown spots called “oil drops”), thickening, crumbling, and separation of the nail from the nail bed (onycholysis).^[6]

Scalp Psoriasis

Scalp involvement is extremely common and can range from mild flaking that resembles dandruff to thick, crusted plaques covering the entire scalp. It can extend beyond the hairline onto the forehead, behind the ears, and down to the nape of the neck.

What Causes Psoriasis?

Psoriasis arises from a combination of genetic susceptibility and environmental triggers. If one parent has psoriasis, a child has about a 10% chance of developing it. If both parents have it, that risk rises to roughly 50%.^[3]

The Immune System Gone Awry

At the molecular level, psoriasis is driven by an overactive immune response. Dendritic cells in the skin become activated and release IL-23, which stimulates T cells to produce IL-17 and IL-22. These cytokines tell skin cells (keratinocytes) to proliferate rapidly and recruit more immune cells, creating a self-perpetuating cycle of inflammation.^[2]

Genetic Factors

Over 80 genetic loci have been linked to psoriasis susceptibility. The strongest association is with HLA-Cw6, a gene in the major histocompatibility complex that plays a role in immune recognition. But genetics alone do not determine who gets psoriasis. Many people carry these gene variants without ever developing the disease. Something has to flip the switch.^[7]

Common Triggers

For people with a genetic predisposition, certain triggers can initiate or worsen psoriasis.

• Stress: This is one of the most commonly reported triggers. Psychological stress can activate immune pathways and worsen skin inflammation through neuroendocrine mechanisms. Many patients can trace their first outbreak to a major stressful life event.^[8]
• Infections: Streptococcal throat infections are the classic trigger for guttate psoriasis, but other infections (including HIV) can also trigger or worsen the disease.
• Skin injury (Koebner phenomenon): Psoriasis can develop at sites of skin trauma, including cuts, scrapes, sunburn, tattoos, and even friction from tight clothing. This phenomenon occurs in 25-50% of psoriasis patients.^[9]
• Medications: Lithium, beta-blockers, antimalarials, and rapid withdrawal of systemic corticosteroids are well-known psoriasis triggers. NSAIDs and ACE inhibitors may also worsen it in some individuals.
• Alcohol: Heavy alcohol consumption is associated with more severe psoriasis and reduced treatment response. Alcohol may worsen psoriasis through its effects on the immune system and liver metabolism of medications.^[10]
• Smoking: Current smokers have nearly double the risk of developing psoriasis compared to people who have never smoked. Smoking is particularly associated with pustular psoriasis of the palms and soles.^[10]
• Cold, dry weather: Many people with psoriasis notice their skin worsens in winter, when humidity drops and there is less natural UV exposure.

Conventional Treatments

Psoriasis treatment is typically stepped based on severity. Mild disease (affecting less than 3% of the body surface) can often be managed topically. Moderate-to-severe disease usually requires phototherapy, systemic medications, or biologics.

Topical Treatments

Corticosteroids remain the most commonly prescribed topical treatment. For psoriasis, medium-to-high potency formulations are often needed given the thickness of the plaques. They reduce inflammation, itch, and scaling effectively but should be used in cycles to avoid side effects like skin thinning.^[11]

Vitamin D analogues (calcipotriol/calcipotriene, calcitriol) slow skin cell growth and are often combined with corticosteroids for enhanced effect. The combination of calcipotriol with betamethasone dipropionate is one of the most effective topical regimens available.

Tar preparations (coal tar) are among the oldest treatments for psoriasis and still work well for some patients, particularly for scalp psoriasis. They reduce scaling, itch, and inflammation, though the smell and staining can be drawbacks.

Topical retinoids (tazarotene) normalize skin cell growth but can cause irritation. They are often combined with a corticosteroid to improve tolerability.

Calcineurin inhibitors (tacrolimus, pimecrolimus), while primarily approved for eczema, are sometimes used off-label for psoriasis in sensitive areas like the face and skin folds.

Phototherapy

Controlled exposure to ultraviolet light is one of the most effective treatments for moderate-to-severe psoriasis. Narrowband UVB (NB-UVB) is the most widely used form, typically administered two to three times per week in a dermatologist’s office or with a home unit. It slows skin cell turnover and reduces inflammation. About 70% of patients achieve significant clearance with NB-UVB.^[12]

PUVA (psoralen plus UVA) involves taking a light-sensitizing medication before UVA exposure. It is very effective but carries a higher long-term risk of skin cancer, so it is used more selectively.

Excimer laser delivers targeted UVB to individual plaques, which is useful for stubborn spots that have not responded to other treatments.

Systemic Medications

When topicals and phototherapy are not enough, oral or injectable systemic medications may be needed.

Methotrexate has been used for psoriasis since the 1950s and remains a reliable option. It suppresses the overactive immune response and is taken once weekly. It requires monitoring of blood counts and liver function, and it cannot be used during pregnancy.^[13]

Cyclosporine works quickly and effectively but is generally limited to short-term use (one to two years) due to risks of kidney damage and high blood pressure.

Acitretin is an oral retinoid that is particularly useful for pustular psoriasis. It works best in combination with phototherapy. Like all retinoids, it is teratogenic and requires strict pregnancy prevention.

Apremilast (Otezla) is a PDE4 inhibitor taken orally that is well-tolerated compared to older systemics. It is less potent than biologics but does not require lab monitoring and may suit patients with mild-to-moderate disease who want an oral option.^[14]

Biologics

Biologic therapies have transformed the treatment of moderate-to-severe psoriasis. These are protein-based drugs, given by injection or infusion, that target specific parts of the immune system.

TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab) were the first wave of biologics for psoriasis. They block TNF-alpha, a major inflammatory cytokine. They remain effective options, though newer agents tend to outperform them.^[15]

IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) target IL-17A, a cytokine central to psoriatic inflammation. They produce high rates of skin clearance, with many patients achieving PASI 90 (90% improvement) or even PASI 100 (complete clearance).^[16]

IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) target the p19 subunit of IL-23, which is upstream in the inflammatory cascade. These agents require fewer injections (often just every 8 to 12 weeks after loading doses) and produce durable, sustained clearance. Risankizumab and guselkumab have shown particularly impressive long-term results.^[17]

IL-12/23 inhibitor (ustekinumab) targets both IL-12 and IL-23. It was one of the first biologics to show that targeting specific interleukins could produce dramatic skin clearance. It requires only four injections per year.

The choice between biologics depends on individual factors including disease severity, comorbidities, convenience, and insurance coverage. Your dermatologist can help navigate these options.

Integrative and Regenerative Approaches

While biologics and other conventional therapies form the backbone of psoriasis treatment, integrative strategies can support overall health and may reduce disease activity.

Anti-Inflammatory Diet

There is growing evidence that diet affects psoriasis severity. A Mediterranean-style diet rich in fruits, vegetables, fish, olive oil, and whole grains has been associated with less severe psoriasis in observational studies. Conversely, diets high in processed foods, sugar, and saturated fat are linked to worse outcomes.^[18]

Weight management deserves special mention. Obesity is both a risk factor for developing psoriasis and a driver of more severe disease. Fat tissue produces inflammatory cytokines (including TNF-alpha) that feed the psoriatic inflammatory cycle. Studies have shown that weight loss, whether through diet, exercise, or bariatric surgery, can significantly improve psoriasis severity and treatment response.^[19]

Some patients report improvement with gluten-free diets, particularly those with elevated antibodies to gliadin. If you suspect gluten sensitivity, a trial elimination with careful monitoring is reasonable, but blanket gluten avoidance is not necessary for everyone with psoriasis.

Vitamin D

Vitamin D plays a well-established role in psoriasis. It regulates keratinocyte growth and differentiation, which is why vitamin D analogues are a mainstay of topical treatment. Low serum vitamin D levels are common in psoriasis patients and are associated with greater disease severity. Supplementation to reach optimal levels (40 to 60 ng/mL) is reasonable and safe for most people, though oral vitamin D alone is not a substitute for direct psoriasis treatment.^[20]

Omega-3 Fatty Acids

Fish oil, rich in EPA and DHA, has anti-inflammatory effects that may benefit psoriasis. A meta-analysis of clinical trials found modest improvements in psoriasis severity with omega-3 supplementation, particularly in patients who were also receiving standard treatment. Doses used in studies typically range from 2 to 4 grams of combined EPA and DHA daily.^[21]

Turmeric and Curcumin

Curcumin, the active compound in turmeric, has documented anti-inflammatory and immunomodulatory properties. Some small clinical studies have shown improvement in psoriasis symptoms with oral curcumin supplementation or topical curcumin preparations. Bioavailability is a challenge with oral curcumin; formulations with piperine (black pepper extract) or phospholipid complexes improve absorption significantly.^[22]

Stress Management

Given the strong link between stress and psoriasis flares, stress reduction is not just a nice idea; it is a therapeutic strategy. Mindfulness-based stress reduction (MBSR), meditation, and cognitive behavioral therapy have all shown benefit in psoriasis patients. One well-known study by Jon Kabat-Zinn found that patients who listened to guided meditation tapes during phototherapy cleared their psoriasis significantly faster than those who received phototherapy alone.^[23]

Red Light Therapy (Photobiomodulation)

Distinct from the UV phototherapy used in clinical settings, red and near-infrared light therapy works through different mechanisms: stimulating mitochondrial function, reducing oxidative stress, and modulating inflammation. While it is not a primary treatment for psoriasis, some studies suggest it may be a helpful adjunct, particularly for localized plaques and for reducing inflammation associated with psoriatic arthritis. More research is needed, but the favorable safety profile makes it worth considering.^[24]

Dead Sea Therapy (Climatotherapy)

Bathing in the mineral-rich waters of the Dead Sea combined with controlled sun exposure has been used for psoriasis treatment for decades. The Dead Sea sits at the lowest point on Earth, and the thick atmosphere filters out some of the sun’s burning rays while allowing therapeutic UVA and UVB through. Studies have shown significant psoriasis improvement with Dead Sea climatotherapy programs, typically lasting three to four weeks. While traveling to the Dead Sea is not practical for everyone, Dead Sea salt baths at home may offer some benefit.^[25]

Psoriasis vs. Eczema: How to Tell Them Apart

These two conditions are sometimes confused, but they are fundamentally different diseases with different underlying mechanisms.

• Appearance: Psoriasis plaques are typically well-defined, thick, and covered with silvery scales. Eczema patches tend to be less defined, thinner, and may weep or crust.
• Location: Psoriasis favors the outer surfaces of joints (elbows, knees), the lower back, and the scalp. Eczema tends to appear in the creases (inner elbows, behind the knees).
• Itch quality: Both conditions itch, but eczema itch is usually more intense and described as burning or stinging. Psoriasis itch is often described as more of a surface-level irritation.
• Age of onset: Eczema commonly starts in infancy and often improves with age. Psoriasis more often begins in adolescence or adulthood.
• Immune pathway: Eczema is Th2-driven; psoriasis is Th17/Th1-driven. This is why they respond to different medications.

It is possible, though uncommon, to have both conditions simultaneously.

Psoriatic Arthritis: The Joint Connection

Up to 30% of people with psoriasis develop psoriatic arthritis (PsA), an inflammatory arthritis that can cause joint pain, stiffness, swelling, and, if untreated, permanent joint damage. PsA can affect any joint but commonly involves the fingers, toes, lower back, and the points where tendons and ligaments attach to bone (enthesitis).^[26]

Early detection is critical. Joint damage from PsA can begin before you notice symptoms, so if you have psoriasis and experience any joint pain, stiffness (especially morning stiffness lasting more than 30 minutes), swollen fingers or toes (“sausage digits”), or lower back pain, bring it up with your doctor promptly.

Many of the biologic treatments used for skin psoriasis are also effective for PsA, which is an advantage for patients dealing with both.

Comorbidities: Psoriasis as a Systemic Disease

Psoriasis is increasingly recognized as more than a skin disease. The chronic systemic inflammation it generates affects multiple organ systems.

Cardiovascular Disease

People with moderate-to-severe psoriasis have a higher risk of heart attack, stroke, and cardiovascular mortality. The chronic inflammation driving psoriasis also promotes atherosclerosis (the buildup of plaques in arteries). This risk exists even after accounting for traditional risk factors like smoking, obesity, and diabetes. Effective treatment of psoriasis may reduce this cardiovascular risk.^[27]

Metabolic Syndrome

Psoriasis is associated with higher rates of obesity, type 2 diabetes, high blood pressure, and abnormal cholesterol levels. The relationship is bidirectional: obesity worsens psoriasis, and psoriasis-related inflammation contributes to metabolic dysfunction.

Mental Health

Depression and anxiety are significantly more common in people with psoriasis than in the general population. The visible nature of the disease, the unpredictability of flares, and the chronic itch all take a psychological toll. Studies have found that the quality-of-life impact of psoriasis is comparable to that of cancer and heart disease.^[28]

This is not something to push through or ignore. If psoriasis is affecting your mood, self-image, or relationships, talk to your healthcare team. Psychological support should be considered part of standard psoriasis care.

The Cost of Treatment

The financial burden of psoriasis is significant. Biologic therapies, while highly effective, carry list prices that often exceed $50,000 to $70,000 per year in the United States. With insurance, copays can still be substantial, though most manufacturers offer patient assistance programs that can significantly reduce out-of-pocket costs.

Even without biologics, the costs add up: topical medications, doctor visits, phototherapy sessions, and lost productivity. Studies estimate the total annual cost of psoriasis in the U.S. at over $100 billion when both direct medical costs and indirect costs (lost work, reduced productivity) are included.^[29]

If cost is a barrier, talk to your dermatologist about it directly. There are often options: patient assistance programs, biosimilars (lower-cost versions of biologic drugs), step therapy approaches, or combinations of less expensive treatments that can still provide good results.

Choosing Between Treatment Options

With so many options available, choosing the right treatment can feel overwhelming. Here are some guiding principles.

1. Match treatment intensity to disease severity. Mild, localized psoriasis may only need topicals. Widespread or resistant disease usually requires systemic therapy.
2. Consider the whole picture. If you also have psoriatic arthritis, a biologic that treats both skin and joints makes more sense than a topical-only approach.
3. Think about lifestyle. How do you feel about self-injections? Can you commit to phototherapy three times a week? Do you need something that works fast for an upcoming event? These practical factors matter.
4. Factor in comorbidities. Some treatments, like methotrexate, require liver monitoring and are not ideal if you consume alcohol regularly. Others, like cyclosporine, are problematic if you have high blood pressure.
5. Set realistic goals. Modern biologics can achieve near-complete clearance for many patients, but this may take several months. Discuss treatment targets with your dermatologist, and give each therapy adequate time before deciding it has failed.
6. Do not neglect the basics. Even on a biologic, consistent moisturizing, trigger avoidance, stress management, and a healthy diet remain important foundations.

The Bottom Line

Psoriasis is a chronic condition, but “chronic” does not have to mean “controlling your life.” The treatment options available today are better than they have ever been, and a growing understanding of the disease is opening doors to even more targeted therapies.

Whether you manage your psoriasis with topical creams, phototherapy, biologics, lifestyle changes, or some combination of all of these, the goal is the same: clear skin, healthy joints, and a life not defined by your diagnosis. Work with a dermatologist who listens, stay informed about new developments, and do not underestimate the value of the integrative strategies that support your whole-body health.

Frequently Asked Questions

How well do biologics work for psoriasis?

According to the guide, IL-17 inhibitors such as secukinumab and ixekizumab can achieve PASI 90 (90% improvement) or even PASI 100 (complete clearance). Newer IL-23 inhibitors like guselkumab and risankizumab require fewer injections, often just every 8 to 12 weeks, and ustekinumab requires only four injections per year. Results from biologics may take several months.

How much do psoriasis biologics cost?

The guide states biologic list prices often exceed $50,000 to $70,000 per year. Overall, psoriasis costs the U.S. over $100 billion annually when both direct medical costs and indirect costs like lost work and reduced productivity are included. For cost-sensitive patients, step therapy approaches or biosimilars are available.

What are the side effects and safety concerns with psoriasis medications?

The guide notes several caveats. Topical corticosteroids should not be used long term due to skin thinning. Methotrexate requires monitoring of blood counts and liver function and cannot be used during pregnancy, cyclosporine is limited to one to two years due to kidney damage and blood pressure risks, and acitretin and other retinoids are teratogenic and require strict pregnancy prevention. PUVA phototherapy carries a higher long-term risk of skin cancer.

Do diet and supplements help with psoriasis?

The guide presents these as integrative approaches alongside conventional care. It describes an anti-inflammatory Mediterranean-style diet, vitamin D supplementation to reach optimal levels of 40 to 60 ng/mL, and 2 to 4 grams of combined EPA and DHA omega-3 daily, though studies show only modest improvements with omega-3. For curcumin, some small clinical studies have shown improvement, but bioavailability is a challenge.

How quickly does phototherapy clear psoriasis?

The guide reports that with narrowband UVB phototherapy, about 70% of patients achieve significant clearance. It also cites one study in which patients who practiced meditation during treatment cleared their psoriasis significantly faster. Dead Sea climatotherapy programs typically last three to four weeks.

Which psoriasis treatment is right for me?

The guide ties treatment to disease severity. Mild disease affecting less than 3% of body surface is typically managed with topicals, while moderate-to-severe disease may call for phototherapy, systemic medications, or biologics. Patients who also have psoriatic arthritis, which affects up to 30% of people with psoriasis, may benefit from biologics that treat both conditions.

References

1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6
2. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004
3. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. doi:10.1038/jid.2012.339
4. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39-42. doi:10.1001/archderm.1992.01680110049004
5. Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144. doi:10.2147/PTT.S98954
6. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1-27. doi:10.1016/j.jaad.2005.07.073
7. Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341-1348. doi:10.1038/ng.2467
8. Basavaraj KH, Navya MA, Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50(7):783-792. doi:10.1111/j.1365-4632.2010.04844.x
9. Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol. 2011;29(2):231-236. doi:10.1016/j.clindermatol.2010.09.014
10. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Clin Exp Dermatol. 2010;35(5):464-468. doi:10.1111/j.1365-2230.2010.03826.x
11. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60(4):643-659. doi:10.1016/j.jaad.2008.12.032
12. Archier E, Devaux S, Castela E, et al. Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):11-21. doi:10.1111/j.1468-3083.2012.04519.x
13. Bangert C, Binder M. Methotrexate in dermatology. Dermatol Ther. 2022;35(1):e15169. doi:10.1111/dth.15169
14. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2015;73(1):37-49. doi:10.1016/j.jaad.2015.03.049
15. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. doi:10.1016/j.jaad.2007.09.010
16. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi:10.1056/NEJMoa1314258
17. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2). Lancet. 2018;392(10148):650-661. doi:10.1016/S0140-6736(18)31713-6
18. Barrea L, Nappi F, Di Somma C, et al. Environmental risk factors in psoriasis: the point of view of the nutritionist. Int J Environ Res Public Health. 2016;13(5):743. doi:10.3390/ijerph13070743
19. Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633-639. doi:10.1159/000455840
20. Orgaz-Molina J, Buendia-Eisman A, Arrabal-Polo MA, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol. 2012;67(5):931-938. doi:10.1016/j.jaad.2012.01.040
21. Clark CCT, Taghizadeh M, Nahavandi M, Jafarnejad S. Efficacy of omega-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials. Clin Rheumatol. 2019;38(4):977-988. doi:10.1007/s10067-019-04456-x
22. Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad Dermatol. 2008;58(4):625-631. doi:10.1016/j.jaad.2007.12.035
23. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med. 1998;60(5):625-632. doi:10.1097/00006842-199809000-00020
24. Ablon G. Phototherapy with light emitting diodes: treating a broad range of medical and aesthetic conditions in dermatology. J Clin Aesthet Dermatol. 2018;11(2):21-27. PMID: 29552273
25. Harari M, Shani J, Hristakieva E, et al. Climatotherapy of atopic dermatitis at the Dead Sea: demographic evaluation and cost-effectiveness. Int J Dermatol. 2000;39(1):59-69. doi:10.1046/j.1365-4362.2000.00840.x
26. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970. doi:10.1056/NEJMra1505557
27. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741. doi:10.1001/jama.296.14.1735
28. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401-407. doi:10.1016/S0190-9622(99)70112-X
29. Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States. JAMA Dermatol. 2015;151(6):651-658. doi:10.1001/jamadermatol.2014.3593
30. Eczema: A Complete Guide to Understanding and Managing Eczema
31. Red Light Therapy: What the Evidence Actually Shows
32. The Anti-Inflammatory Diet: A Practical Guide
33. Vitamin D: Why Most People Are Deficient and What to Do About It